scholarly journals Main phenotypes and histological types of breast cancer in young women attended at a reference hospital in women’s health in the city of São Paulo

2020 ◽  
pp. BMT53
Author(s):  
Guilherme Moreno Rodrigues de Souza ◽  
Anderson Fernandes Carvalho ◽  
Simone Ferreira Santiago ◽  
Maria Aparecida M R Pinho ◽  
Débora Ribeiro Ramadan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Young Women ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Luminal B ◽  
High Prevalence ◽  
Reference Hospital ◽  
Triple Negative Phenotype ◽  
The City

It is estimated that there were 198,840 new cases of breast cancer (BC) in Brazil between 2020 and 2022. Young women who are affected by invasive BC with a triple-negative phenotype generally present more aggressive tumors that are intrinsically resistant to targeted therapies. This study evaluated the phenotypic and histological profile of BC in women up to the age of 40 years. Between 2015 and 2017, we identified 255 women with positive biopsy for carcinoma and with immunohistochemical panel, 51.76% who had a profile for luminal B (n = 132); 22.74% for triple-negative (n = 58). Of the samples, 65.88% presented histology as invasive ductal carcinoma – nonspecial type (n = 168). The results are in accordance with the literature regarding the high prevalence of triple-negative BC in young women and histological type invasive ductal carcinoma – nonspecial type.

Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2- primary breast cancer.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 141-141
Author(s):  
Katsuhiko Nakatsukasa ◽  
Tetsuya Taguchi ◽  
Hiroshi Koyama ◽  
Seiichi Imanishi ◽  
Kouichi Sakaguchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Primary Breast Cancer ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Dose Intensity ◽  
Completion Rate ◽  
Luminal A ◽  
Luminal B ◽  
Triple Negative Subtype

141 Background: Recently, docetaxel plus cyclophosphamide (TC) has been established as a standard regimen for adjuvant chemotherapy in HER2- operable breast cancer. However, the efficacy and tolerability of TC as neoadjuvant chemotherapy (NAC) remains unclear. We performed a prospective study of TC NAC in HER2- primary breast cancer. Methods: Eligible patients had HER2- invasive breast cancer that measured more than 1cm, less than 7cm and N0~N1 clinically between July, 2011 and February, 2014. Four cycles of TC(75 and 600 mg/m2) were administered intravenously every 3 weeks as NAC. We investigated the pathological complete response(pCR) of primary breast tumors. pCR was defined as no histological evidence of invasive carcinoma, or the appearance of only ductal carcinoma in situ. The cut-off value of Ki67 index between luminal A and luminal B was defined 20%. Results: We enrolled 52 patients. The completion rate for 4 cycles of TC was 94.2% ( 49 of 52). Relative dose intensity was 99.1% for TC therapy. Forty nine patients were classified according to breast cancer subtype before the estimation. Overall pCR rate was 16.3 %( 8 of 49 ) . pCR rate for patients with luminal A ( ER+, Ki67 low and HER2- ), luminal B ( ER+, Ki67 high and HER2- ) and triple negative ( ER- and HER2- ) were 0%( 0 of 12 ), 4.3 %( 1 of 23 ) and 50.0 %( 7 of 14 ), respectively pCR was achieved in almost triple negative patients. Conclusions: The pCR rate of TC was not so high, regardless of the high completion rate. In this study, TC was effective against triple negative subtype, showing a high pCR rates, compared with luminal subtype. In conclusion, the efficacy of TC NAC in HER2- primary breast cancer is limited, and triple negative subtype might be the good target. Clinical trial information: UMIN000013261.

scholarly journals Triple Negative Breast Cancer in Pregnancy and Postpartum: Two Case Reports in Hispanic Women

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Ruchi Upadhyay ◽  
Qurat-Ul-Ain Butt ◽  
Abraham Hamaoui ◽  
Cassandra Henderson ◽  
Sydney McCalla ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Hispanic Women ◽  
African Ancestry ◽  
Radical Mastectomy ◽  
Unique Challenge ◽  
Pregnancy And Postpartum

Objective. Despite studies suggesting that triple negative breast cancer is more often seen in women of African ancestry, we report here two cases of pregnancy associated triple negative breast cancer in Hispanic women.Cases. Case one is a 37-year-old female para 2-0-0-2, who presented with a left breast mass, at 19 weeks of gestation, the biopsy of which reported an invasive ductal carcinoma, found to be triple receptor negative. The patient underwent chemotherapy during the pregnancy and was delivered with a cesarean at 37 weeks for obstetric indication. After delivery, the patient completed her chemotherapy that was followed by radical mastectomy and radiotherapy. Case two is a 28-year-old female para 6-0-1-5, who presented while breast-feeding with signs and symptoms of mastitis, and an engorged and tender right breast, five months postpartum. However, the sonogram revealed a fluid filled cavity. Aspiration and cytology did not reflect an infection and were negative for malignancy. High suspicion and lack of improvement led to biopsy that identified an invasive ductal carcinoma, found to be triple negative. The patient underwent chemotherapy followed by modified radical mastectomy.Conclusions. Triple negative breast cancer, during pregnancy or postpartum, poses a unique challenge and requires a multidisciplinary team to optimize treatment for these women.

scholarly journals Concurrent Down-regulation of the EAF1 and the EAF2 Genes in the Invasive Ductal Carcinoma Type of Breast Cancer

2021 ◽  
Vol 11 (2) ◽  
pp. 1620-1628
Author(s):  
Sogand Heydaran
Keyword(s):  
Breast Cancer ◽  
Tumor Suppressor ◽  
Real Time ◽  
Invasive Ductal Carcinoma ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Rna Extraction ◽  
P Value ◽  
Control Analysis ◽  
Down Regulation

In mammals, the EAF1 and EAF2 genes build an active transcription module with other components. These genes code for factors acting as potent inhibitor of the Wnt-β catenin pathway, which might be due to their function as tumor suppressor gene. Recently, the involvement of both above-mentioned factors was described in some human tumors, but not yet in breast cancer. Breast cancer is one of the most cancer cases in Iran after colon and stomach carcinoma. We aimed therefore to investigate for the first time a possible correlation between breast cancer and the EAF1 and the EAF2 gene expression. We collected invasive ductal carcinoma tumor grading (grade 1 to 3) with marginal normal tissue from forty women diagnosed with breast cancer with the average age of 50 years old. All patients underwent triple marker test (ER/PR and Her2/neu), indeed the most of them were triple positive with few triple negative individuals. After RNA extraction, cDNA was synthesized for subsequent real-time polymerase chain reaction. The humanRPL27 gene wasusedas endogenous control. Analysis of real-time PCR results showeda significant down-regulation of EAF1 (p-value: 0.028), and of EAF2 (p-value: 0.0134) in tumor tissue samples in comparison to normal one.There was no correlation between clinical parameters and the target genes. We could find significant connection between both tumor suppressor genes in triple positive and triple negative breast cancer patients, which deserves more attention.

Sign in / Sign up

Export Citation Format

Share Document